Expanded Access to Upadacitinib
In the register
The register attaches this trial to Upadacitinib (Rinvoq) (AbbVie), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Available (expanded access)
- Declared phase
- No phase declared
- Sponsor
- AbbVie
- Participants (registry)
- —
- Start
- —
- Primary completion
- —
- Study completion
- —
- Last registry update
- August 2026
- Countries
- —
Conditions studied: Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Non-radiographic Axial, Spondyloarthritis, Giant Cell Arteritis, Systemic Lupus Erythematosus, Alopecia Areata, Non Segmental Vitiligo, Hidradenitis Suppurativa
Interventions: Upadacitinib, ABT-494, Rinvoq, C25-267
Other trials of Upadacitinib (Rinvoq)
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.